We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

A Study of Resveratrol as Treatment for Friedreich Ataxia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01339884
Recruitment Status : Completed
First Posted : April 21, 2011
Last Update Posted : January 22, 2014
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to determine the effect of two doses of resveratrol taken for a 12 week period, on frataxin levels in individuals with Friedreich ataxia. This study will also measure the effect of resveratrol on markers of oxidative stress, clinical measures of ataxia, and cardiac parameters.

Condition or disease Intervention/treatment Phase
Friedreich Ataxia Drug: Resveratrol Phase 1 Phase 2

Detailed Description:
Resveratrol shows promise as an agent for the treatment of Friedreich ataxia due to its antioxidant properties, neuroprotective effects, and ability to increase frataxin levels in vitro and in vivo. This clinical pilot study aims to determine the effect of two doses of resveratrol (1g/day and 5g/day) taken for 12 weeks, on frataxin levels in individuals with Friedreich ataxia. Additional outcome measures include the effect of resveratrol on markers of oxidative stress, clinical measures of ataxia , and cardiac parameters (including relative wall thickness and left ventricular mass index).

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 27 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Clinical Pilot Study of Resveratrol as Treatment for Friedreich Ataxia
Study Start Date : April 2011
Primary Completion Date : August 2012
Study Completion Date : December 2012


Arms and Interventions

Arm Intervention/treatment
Active Comparator: Resveratrol, 1g daily
15 participants will receive resveratrol 1g daily
Drug: Resveratrol
Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
Active Comparator: Resveratrol, 5g daily
15 participants will receive resveratrol, 5g daily
Drug: Resveratrol
Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks


Outcome Measures

Primary Outcome Measures :
  1. Lymphocyte frataxin level [ Time Frame: 12 weeks ]
    Change in lymphocyte frataxin levels at 12 weeks compared to baseline


Secondary Outcome Measures :
  1. Oxidative stress markers [ Time Frame: 12 weeks ]
    Oxidative stress, as measured by a) plasma F2-isoprostanes and b) urinary 8-hydroxyl-2-deoxyguanosine levels at 12 weeks compared to baseline

  2. Clinical rating scales of ataxia [ Time Frame: 12 weeks ]
    Clinical rating scales of ataxia at 12 weeks will be compared to baseline. This will include: a) Friedreich Ataxia Rating Scale (FARS) b) International Cooperative Ataxia Rating Scale (ICARS) c) Scale for the Assessment and Rating of Ataxia (SARA) d) Friedreich Ataxia Functional Composite

  3. Echocardiogram measures [ Time Frame: 12 weeks ]
    Changes in structural and functional 3D echocardiogram measures from baseline to 12 weeks will be reported

  4. Pharmacokinetic studies of resveratrol [ Time Frame: First 2 hours post dose ]
    Pharmacokinetic data will be collected 45, 90 and 120 minutes after the first dose of resveratrol. Plasma concentration of resveratrol and its sulfate and glucuronide metabolites will be measured in ng/mL.


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults with Friedreich ataxia due to homozygosity for the GAA repeat expansion in intron 1 of the FXN gene
  • Functional stage on the Ataxia subscale of the FARS of 1 or higher

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Active arrythmias or significant cardiac insufficiency
  • Use of idebenone, Coenzyme Q or vitamin E within 30 days prior to enrolment
  • Use of amiodarone or other medications which may have clinically significant drug interactions that cannot be safely monitored
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01339884


Locations
Australia, Victoria
Monash Medical Centre, Southern Health
Clayton, Melbourne, Victoria, Australia, 3168
Sponsors and Collaborators
Murdoch Childrens Research Institute
Friedreich's Ataxia Research Alliance
Investigators
Principal Investigator: Martin Delatycki, MBBS PhD Murdoch Childrens Research Institute
More Information

Responsible Party: Martin Delatycki, Prof Martin Delatycki, Murdoch Childrens Research Institute
ClinicalTrials.gov Identifier: NCT01339884     History of Changes
Other Study ID Numbers: 10358B
First Posted: April 21, 2011    Key Record Dates
Last Update Posted: January 22, 2014
Last Verified: January 2014

Keywords provided by Martin Delatycki, Murdoch Childrens Research Institute:
Friedreich ataxia
Resveratrol
Frataxin
Cardiomyopathy
Oxidative stress

Additional relevant MeSH terms:
Ataxia
Cerebellar Ataxia
Friedreich Ataxia
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Cerebellar Diseases
Brain Diseases
Central Nervous System Diseases
Spinocerebellar Degenerations
Spinal Cord Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Mitochondrial Diseases
Metabolic Diseases
Resveratrol
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action